On behalf of the Canadian VIGOUR Centre (CVC) and the Beyond 2018 (B2K18) educational program, we are pleased to share a Canadian Cardiovascular Society-accredited webinar series initiative that is being provided as an extension to the B2K18 symposium (held annually during the Canadian Cardiovascular Congress, most recently October 22, 2018). The 3rd webinar in this […]
On behalf of the Canadian VIGOUR Centre (CVC) and the Beyond 2018 (B2K18) educational program, we are pleased to share a Canadian Cardiovascular Society-accredited webinar series initiative that is being provided as an extension to the B2K18 symposium (held annually during the Canadian Cardiovascular Congress, most recently October 22, 2018). The second webinar in this […]
We are pleased to share with you the Winter 2018 issue of the Canadian Cardiac Chronicle. This issue features: A letter from Founding Director Dr. Paul W. Armstrong on the importance of reliable research and scientific literacy Recent updates from current and upcoming clinical trials Information about upcoming 2019 events, including ACC Rockies,the CVC Clinical […]
The CVC is pleased to announce the addition of two new associate faculty members. Dr. Sean McMurtry is a clinician scientist and Associate Professor in the Division of Cardiology. Dr. McMurtry is engaged in basic and clinical research projects studying coronary artery disease, peripheral artery disease, venous thromboembolism, and thoracic aortic disease. Dr. Roopinder Sandhu […]
On behalf of the Canadian VIGOUR Centre (CVC) and the Beyond 2018 (B2K18) educational program, we are pleased to share a Canadian Cardiovascular Society-accredited webinar series initiative that is being provided as an extension to the B2K18 symposium (held annually during the Canadian Cardiovascular Congress, most recently October 22, 2018). The first webinar in this […]
Congratulations to the ODYSSEY OUTCOMES team on the publication of Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome in The New England Journal of Medicine. The ODYSSEY OUTCOMES clinical trial sought to determine whether alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary […]
The CVC is pleased to share that our organization’s Founding Director, Dr. Paul W. Armstrong, has been appointed as Chair of the Institute of Health Economics (IHE) Board of Directors, effective October 1, 2018. More information on this appointment can be found on the IHE’s website here (Photo: Richard Siemens ©️university of Alberta)
We are pleased to share with you the Summer 2018 issue of the Canadian Cardiac Chronicle. This issue features: A letter from Co-Director Shaun Goodman about patient-oriented research; Recent updates from current and upcoming clinical trials; An update on the ICH GCP E6 guidelines; An announcement about the CVC’s 2017 Annual Report Information about the […]
Congratulations to Dr. Kevin Bainey, who was featured in the Edmonton Journal, speaking to his recently published article “Population-level incidence and outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA): Insights from the Alberta contemporary acute coronary syndrome patients invasive treatment strategies (COAPT) study”, which was also coauthored by several other members of the CVC […]
